Publications by authors named "R B R Leon-Cachon"
Article Synopsis
- Atorvastatin (ATV) is a cholesterol-lowering drug crucial for preventing cardiovascular deaths, and this study aims to identify genetic factors affecting its metabolism among individuals.
- A clinical trial with 60 healthy Mexican men evaluated ATV levels after a single dose, revealing four metabolizer phenotypes: slow, intermediate, normal, and fast.
- Six genetic polymorphisms were found to significantly impact ATV pharmacokinetics, with SLCO1B1 and ABCB1 variants playing a key role in the metabolism of the drug, highlighting the genetic basis for variability in drug responses.*
: Vitelliform Macular Dystrophy is an inherited autosomal dominant disease with variable expressivity, caused by a mutation in the gene. We report a family with variable expressivity and incomplete penetrance in its members.: A Mexican family was studied.
View Article and Find Full Text PDFAssociation study of genetic polymorphisms in proteins involved in oseltamivir transport, metabolism, and interactions with adverse reactions in Mexican patients with acute respiratory diseases.
Pharmacogenomics J
August 2020
Oseltamivir, a pro-drug, is the best option for treatment and chemoprophylaxis for influenza outbreaks. However, many patients treated with oseltamivir developed adverse reactions, including hypersensitivity, gastritis, and neurological symptoms. The aim of this study was to determine the adverse drug reactions (ADRs) in Mexican patients treated with oseltamivir and whether these ADRs are associated with SNPs of the genes involved in the metabolism, transport, and interactions of oseltamivir.
View Article and Find Full Text PDFBackground: Sex bias in immune function has been contributed in part to a preponderance of immune system-related genes (ISRG) on the X-chromosome. We verified whether ISRG are more abundant on the X chromosome as compared to autosomal chromosomes and reflected on the impact of our findings.
Methods: Consulting freely accessible databases, we performed a comparative study consisting of three complementary strategies.
Amfepramone (AFP) is an appetite-suppressant drug used in the treatment of obesity. Nonetheless, studies on interindividual pharmacokinetic variability and its association with genetic variants are limited. We employed a pharmacokinetic and pharmacogenetic approach to determine possible metabolic phenotypes of AFP and identify genetic markers that could affect the pharmacokinetic variability in a Mexican population.
View Article and Find Full Text PDF